Effect of atorvastatin on hs-CRP in acute coronary syndrome.
OBJECTIVE
To evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS.


METHODS
Group A (n = 50) patients received atorvastatin 20 mg day(-1) for 4 weeks in addition to standard anti-anginal treatment. Group B (n = 50) patients received standard anti-anginal treatment without atorvastatin.


RESULTS
hs-CRP concentrations decreased in both groups, but the decrease was greater in group A. The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin.


CONCLUSIONS
The use of a lower dose (20 mg) of atorvastatin can offer an attractive approach for early treatment of patients with ACS.
Gupta
Ankur
A
Department of Pharmacology, Christian Medical College and Hospital, Ludhiana-141 008, India.
Badyal
Dinesh K
DK
Khosla
Prem P
PP
Uppal
Bharti
B
Jaison
Thannikot M
TM
Chopra
Sandeep
S
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D008078:Cholesterol, LDL / Q000187:drug effects* / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D008055:Lipids; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin